Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

483 Reports from FirstWord

   
  • Commercialisation of Biologics: Benchmarking leading players

    ... are obviously attractive, but just how effective have biologics manufacturers been so far in commercialising these innovative drugs? How have key players navigated stumbling blocks such as inconsistent patient and physician acceptance and growing payer ... Read More

  • Customer Engagement: Benchmarking Pharma Companies

    ... away from the brand focus of old and develop new customer-focused engagement strategies. What have the front-runners achieved so far and how have they tackled this new challenge? Customer Engagement: Benchmarking Leading Pharma Companies provides ... Read More

  • Medical Affairs Reputations (US) [Parkinson's Disease]

    ... Disease medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and ... Read More

  • Medical Affairs Reputations (EU5) [Parkinson's Disease]

    ... Germany, Italy and Spain) the performance of Parkinson's Disease medical affairs teams still has a way to go in some key areas. Find out what physicians think is done well; what they want to see ... Read More

  • Medical Affairs Reputations (US) [RA]

    ... Use Medical Affairs Reputations: Rheumatoid Arthritis 2017 (US) to discover how your team can better meet the high expectations of physicians at the frontline. This report compares the current activities of medical affairs teams for ... Read More

  • NPS+ (US) [Myeloma]

    ... achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ Multiple Myeloma ... Read More

  • Value Added Services in Cardiometabolic Diseases -- Payer views

    ... quietly dropped post launch. No wonder there is a widespread cynical view among payers that many ""beyond the pill"" support services are little more than a marketing ploy. How can Pharma get back on track ... Read More

  • The Future of Market Access in Europe

    ... cost-cutting and budgetary pressures. At the same time, the healthcare world keeps on turning and pharma must continue to push forward and ensure the latest drugs reach the patients they are designed for. But what ... Read More

  • Innovative drugs: Mapping the pricing, reimbursement and HTA landscape

    ... 58 innovative medicines were approved and launched in the US - but what of their status elsewhere? For example, only 35 of the 58 have been approved in the EU and of these many are ... Read More

  • Prostate Cancer [2017]

    ... does the future hold? Key opinion leaders (KOLs) are excited about expanded approvals for hormonal therapies and personalised approaches with PARP inhibitors and PD-1/PD-L1 immunotherapies, but which therapy will stand out in an evolving and ... Read More

  • Riding the Wearable Trend: Opportunities for Pharma

    ... improved patient monitoring and adherence to generating real-world, real-time data that underpins value claims with payers and stakeholders. But how can you separate the hype from the real potential? Riding the Wearables Trend: Opportunities for ... Read More

  • Medical Affairs Reputations (EU5) [RA]

    ... Italy and Spain) the performance of rheumatoid arthritis medical affairs teams still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more ... Read More

  • NPS+ (EU5) [Myeloma]

    ... achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ Multiple Myeloma ... Read More

  • Alzheimer's Disease [2017]

    ... Is the amyloid hypothesis dead or could the right drug candidate, studied in an optimally designed trial, gain approval for this much sought after indication? KOLs weigh in on how trials could be optimised and ... Read More

  • The Future of Market Access in US

    ... continue to rage, pharma initiatives are having lacklustre impact, and payers are still not happy. At the same time, the US President is waxing lyrical about sweeping change which most of the industry expect will ... Read More

  • The Future of Biosimilars in the USA: Mapping critical uncertainties and the impact of future events

    ... in the US? Is too much focus on legal wrangling stifling healthy competition and innovation? And, as the arguments rage,is the patient being forgotten? This report looks at recent progress on biosimilars penetration in the ... Read More

  • Market Access Impact (US) [Cancer Pain]

    ... US, and most brands lose market share because of them. According to the medical oncologists we surveyed, that’s a problem with no single solution; many of them experience as many as 3 different barriers with ... Read More

  • Market Access Impact (EU5) [Cancer Pain]

    ... brands gain market share because of them, but for some brands, perception may be an even bigger problem. And over 10% of doctors either wouldn’t prescribe these brands, or simply haven’t heard of them at ... Read More

  • Market Access Impact (EU5) [Myeloma]

    ... and the split between brands that gain and lose market share because of them is pretty even. But a willingness to prescribe certain brands, and high levels of awareness, could be the light at the ... Read More

  • Multiple Myeloma [2017]: Bulletin #1

    ... ALCYONE of Johnson & Johnson’s and Genmab’s Darzalex (daratumumab) in combination with Velcade (bortezomib; Takeda), melphalan and prednisone (VMP) versus VMP alone, as front-line treatment for newly diagnosed patients who are not considered candidates for ... Read More

  • Ulcerative Colitis [2017]

    ... landscape. While Pfizer’s JAK inhibitor clearly has a head-start, other companies have more selective JAK1-inhibitors in late-stage development, including AbbVie’s upadacitinib and Galapagos/Gilead Sciences’ filgotinib. Celgene has taken a different approach with its oral molecule, ... Read More

  • Colorectal Cancer [2017]

    ... while Keytruda (pembrolizumab; Merck & Co.) and Opdivo (nivolumab; Bristol-Myers Squibb) represent the most recent additions to the CRC treatment armamentarium, do KOLs believe they’ll make an impact? An array of programmes are in late-stage ... Read More

  • Medical Affairs Reputations (US) [Asthma/COPD]

    ... of asthma/COPD medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; ... Read More

  • Medical Affairs Reputations (EU5) [Asthma/COPD]

    ... (UK, France, Germany, Italy and Spain) the performance of asthma/COPD medical affairs teams still has a way to go in some key areas. Find out what physicians think is done well; what they want to ... Read More

  • Key Success Factors in Pricing, Reimbursement and Market Access

    ... goalposts keep being moved as payer policies, needs and attitudes evolve. In an ever-changing market access landscape how can pharma companies renew or upgrade their commercialisation strategies? Key Success Factors in Pricing, Reimbursement and Market ... Read More

1 2 3 4 6 8 9 10

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook